Molecular targets, such as epidermal growth factor receptor (EGFR), mammalian target of rapamycin (mTOR), and c-MET, have shown significant involvement in the aggressiveness of gastric adenocarcinomas. Here, EGFR is linked to gastric adenocarcinoma.